Navigation Links
Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
Date:3/17/2009

INDIANAPOLIS, March 17 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company (NYSE: LLY) announced its support for the Pathway for Biosimilars Act. The U.S. has a 25-year history of success with laws promoting the discovery of new, chemical-based medicines and providing an abbreviated approval process under which generic versions of those new medicines can to come to market. But Congress has yet to take that step with the most advanced new medicines, called biological drugs or simply "biologics."

Lilly said the Pathway for Biosimilars Act, reintroduced in the 111th Congress by Reps. Anna Eshoo (D-Calif.), Jay Inslee (D-Wash.) and Joe Barton (R-Texas), would successfully create a pathway that carefully weighs the needs of patients and stakeholder companies. This balance, Lilly said, would assure patients and payers the benefits that come from greater competition, preserve incentives for biotechnology innovation and foster investments that will produce more high-paying jobs in the life sciences.

"Lilly commends Representatives Eshoo, Inslee and Barton for joining together and introducing a carefully considered, balanced approach to ensuring the promise of biotech medicine becomes a reality for patients," said Robert Armitage, Lilly's senior vice president and general counsel. "Making biotech discoveries entails many years of research, massive investments and high risk. This bill makes certain that innovator companies can continue to make these types of investments in new therapies for patients, and that, once a reasonable period of time has passed for recouping its investment, generic companies can copy those innovations in a safe, scientifically sound manner."

The key provision of the Eshoo-Inslee-Barton bill striking this balance is the 14-year "data protection period." The legislation's formula would offer al
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions
2. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
3. Millipore Launches an Interactive Biological Pathway Tool Using GeneGos Manually Curated Pathway Maps
4. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
5. GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award
8. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
9. Pathway Diagnostics Announces Commercial Availability of Second Generation SensiTrop(TM) II Molecular HIV Co-receptor Tropism Assay
10. Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimers Disease
11. Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 Today the Academy ... the United States Court of Appeals for the D.C. Circuit ... Aircraft published in the Federal Register on June 25, 2014. ... is contrary to the text and intent of the FAA ... violates Congress’ specific prohibition on any new rules or regulations ...
(Date:8/22/2014)... form and develop on platinum nanocubes point the ... and reveal that a nearly 150 year-old scientific ... nanoscale. , Researchers with the U.S. Department of ... used highly sophisticated transmission electron microscopes and an ... mechanisms that control the evolution of facets ...
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global and China Gel Permeation Chromatography (GPC) Industry Report ... The Global and China Gel Permeation Chromatography (GPC) Industry ... current state of the global gel permeation chromatography industry ... report provides a basic overview of the industry including ...
(Date:8/22/2014)... 2014 The identification of protein-coding ... be accelerated by exome sequencing. Built on Roche ... custom SeqCap EZ Developer system has been a ... will additionally present how he achieved coverage statistics ... and mouse exome kits. With over 236,000 SNPs ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... Va., Aug. 13 According to new research ... market,research and consulting firm serving the life science ... must innovate to find new ways to,demonstrate customer ... equipment manufacturer (OEM), in-house and a,combination of all ...
... the,appointment of David A. Mann to the Company,s Board ... Board,s audit committee., "Dave,s years of executive management ... an invaluable asset to Omeros,",stated Gregory Demopulos, M.D., Chairman ... our Board, and I expect that he will play ...
... 2:00 p.m. CET, AMSTERDAM, August 13 Amsterdam Molecular,Therapeutics ... therapy,today reported its results for the first half year of ... trial for Glybera(R) (AMT-011) for Hyperlipoproteinemia type I ... - License for treatment of Duchenne Muscular Dystrophy from ...
Cached Biology Technology:BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 2BioInformatics, LLC Offers Solutions for Optimizing Service and/or Maintenance Contracts 3Omeros Appoints David A. Mann to its Board of Directors 2Amsterdam Molecular Therapeutics Reports Half Year Results 2008 2Amsterdam Molecular Therapeutics Reports Half Year Results 2008 3Amsterdam Molecular Therapeutics Reports Half Year Results 2008 4
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information ... the University of California, Riverside in its 2014 list ... our times." , To generate the list, the company ... researchers whose published work has had enormous impact. , ... 3,200 individuals who published the greatest number of highly ...
(Date:8/22/2014)... Jolla, CA Research presented at the 29th ... being developed by Hera Therapeutics Inc. combats three ... cause 70 percent of all cervical cancer. , ... HTI-1968 blocked the replication of HPV-16, HPV-18 and ... and Thomas Broker, Ph.D., who presented the findings ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... have linked an overactive response by one of the immune ... cells to the onset of biliary atresia in infants, ... damage and death. Researchers at Cincinnati Children,s Hospital Medical ... cells attack bile duct tissues lessens damage and may be ...
... temporal variability in crop yields has implications for sustainable ... are projected with global climate change. Many long-term ... study looked at stability of yields and whether cropping ... poor- and high- yielding years. K.K. Grover ...
... Singapore and Washington DC (July 20, 2009) Genetic testing ... patient, and the results of the consumers, response can affect ... testing, according to a position paper from the American College ... 2009 issue of the Journal of Clinical Pharmacology . ...
Cached Biology News:Scientists link immune system's natural killer cells to infant liver disease 2Genetic tests advertised directly to the consumer 2
... Turner (1997). • This book describes ... the production of high-quality antibodies, the ... standardisation of antibodies and antigens, the ... enzyme immunoassays for detecting cell-surface molecules ...
... The 1-D PAGE ... Kit for Targeted Protein ... SDS PolyAcrylamide Gel Electrophoresis ... chemistry, and cleavable-linker technology ...
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: